Table 3 Comparison in safety between RCA and heparin anticoagulation for IHD
Variables | Before inverse probability of treatment weighting | After inverse probability of treatment weighting | |||||
|---|---|---|---|---|---|---|---|
IHD sessions with RCA (n = 124) | IHD sessions with heparin (n = 84) | p-value | IHD sessions with RCA (n = 112) | IHD sessions with heparin (n = 82) | p-value | |d| | |
Calcium gluconate infusion for hypocalcemia during session, n (%) | 10 (8.1) | 1 (1.2) | 0.008 | (6.9) | (2.1) | 0.22 | 0.235 |
Hemorrhagic events, n (%) | Â | Â | Â | Â | Â | 0.15 | Â |
 Type I | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) |  | NA |
 Type II | 2 (1.6) | 0 (0) | 0.52 | (2.7) | (0) |  | 0.235 |
 Type III | 5 (4) | 7 (8.3) | 0.21 | (3.8) | (8.9) |  | 0.211 |
Interventions for hemodynamic instability, n(%) | |||||||
 Ultrafiltration stopping | 12 (9.7) | 16 (19.1) | 0.11 | (9.0) | (17.8) | 0.09 | 0.261 |
 Fluid bolus | 5 (4) | 6 (7.1) | 0.33 | (3.7) | (7.1) | 0.29 | 0.151 |
 Increasing dose of vasopressor amine | 22 (17.7) | 19 (22.6) | 0.08 | (14.7) | (20.6) | 0.29 | 0.155 |
Causes of premature termination of session, n (%) | |||||||
 Hemodynamic instability | 6 (4.8) | 6 (7.1) | 0.49 | (4.4) | (9.1) | 0.22 | 0.188 |
 Catheter dysfunction | 7 (5.6) | 7 (8.3) | 0.37 | (5.5) | (11.4) | 0.16 | 0.213 |
 Acute high transmembrane pressure | 26 (21) | 6 (7) | 0.02 | (20.2) | (8.8) | 0.03 | 0.327 |
 Circuit clotting | 16 (12.9) | 2 (2.4) | 0.02 | (12.2) | (2.9) | 0.02 | 0.355 |